



Freedom of Information Request: Our Reference CTMUHB_84_26

You asked:

Q1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?

Eight (8).

Q2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

- **BR (Bendamustine + rituximab) = 0**
- **VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) = 0**
- **R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) = ****
- **R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) = 0**
- **CVP (cyclophosphamide, vincristine and prednisolone) = 0**
- **Brukinsa (zanubrutinib) = 0**
- **Imbruvica (ibrutinib) = 5**
- **Velcade (bortezomib) + chemotherapy = 0**
- **Tecartus (brexucabtegene autoleucel) = 0** (commissioned to [Cardiff and Vale University Health Board \(CAVUHB\)](#) for further information, please contact them directly via the link provided)
- **R-BAC (rituximab, bendamustine and cytarabine) = 0**
- **R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) = 0**
- **Any other systemic anti-cancer therapy = 0**
- **Wait and watch (monitoring only, no active treatment)** – The Health Board does not record this information centrally and has concluded that the information is exempt under Section 40 (2) of the Freedom of Information Act (detailed as below) on the basis that individual patient records would need to be reviewed to ascertain the information.

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection

Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

For this question, please only count patients that have received the below treatments for the first time.

- **BR (Bendamustine + rituximab) = 0**
- **VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) = 0**
- **R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) = ****
- **R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) = 0**
- **CVP (cyclophosphamide, vincristine and prednisolone) = 0**
- **Brukinsa (zanubrutinib) = 0**
- **Imbruvica (ibrutinib) = 0**
- **Velcade (bortezomib) + chemotherapy = 0**
- **Tecartus (brexucabtegene autoleucel) = 0 (CAVUHB commissioned)**
- **R-BAC (rituximab, bendamustine and cytarabine) = 0**
- **R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) = 0**
- **Any other systemic anti-cancer therapy = 0**
- **Wait and watch (monitoring only, no active treatment) – The Health Board does not record this information centrally and has concluded that the information is exempt under Section 40 (2) of the Freedom of Information Act on the basis that individual patient records would need to be reviewed to ascertain the information.**

Q4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.

No.